Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Hold" from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been assigned a consensus recommendation of "Hold" from the four research firms that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $11.33.

TBPH has been the topic of a number of analyst reports. Jones Trading began coverage on shares of Theravance Biopharma in a research note on Tuesday. They issued a "buy" rating and a $24.00 price objective for the company. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 24,000 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.00, for a total transaction of $264,000.00. Following the transaction, the senior vice president now owns 336,918 shares of the company's stock, valued at approximately $3,706,098. This represents a 6.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TBPH. Nuveen LLC bought a new stake in shares of Theravance Biopharma in the first quarter valued at approximately $3,348,000. Newtyn Management LLC boosted its holdings in Theravance Biopharma by 5.7% in the 4th quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock valued at $44,767,000 after purchasing an additional 258,337 shares during the period. Acadian Asset Management LLC boosted its holdings in Theravance Biopharma by 121,993.7% in the 1st quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock valued at $1,554,000 after purchasing an additional 174,451 shares during the period. Dimensional Fund Advisors LP grew its position in Theravance Biopharma by 20.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock worth $5,211,000 after purchasing an additional 95,304 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in shares of Theravance Biopharma by 169.2% during the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock worth $1,258,000 after purchasing an additional 88,540 shares during the period. Institutional investors own 99.10% of the company's stock.

Theravance Biopharma Price Performance

NASDAQ TBPH opened at $10.75 on Tuesday. The company's 50 day simple moving average is $9.61 and its 200 day simple moving average is $9.45. The firm has a market capitalization of $537.51 million, a PE ratio of -10.64 and a beta of -0.09. Theravance Biopharma has a 12 month low of $7.44 and a 12 month high of $11.82.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The business had revenue of $15.39 million for the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. Sell-side analysts anticipate that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.